About Intellia Therapeutics
Intellia Therapeutics is a company based in Cambridge (United States) founded in 2014.. Intellia Therapeutics has raised $85.02 million across 2 funding rounds from investors including Fidelity Investments, Novartis and Orbimed. The company has 403 employees as of December 31, 2024. Intellia Therapeutics has completed 1 acquisition, including Rewrite Therapeutics. Intellia Therapeutics offers products and services including Nexiguran Ziclumeran and CRISPR Programs. Intellia Therapeutics operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Cambridge, United States
- Employees 403 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Intellia Therapeutics, Inc.
-
Annual Revenue
$57.88 M59.55as on Dec 31, 2024
-
Net Profit
$-519.02 M-7.86as on Dec 31, 2024
-
EBITDA
$-523.98 M-3.49as on Dec 31, 2024
-
Total Equity Funding
$85.02 M (USD)
in 2 rounds
-
Latest Funding Round
$70.02 M (USD), Series B
Sep 01, 2015
-
Investors
Fidelity Investments
& 7 more
-
Employee Count
403
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Intellia Therapeutics
Intellia Therapeutics is a publicly listed company on the NASDAQ with ticker symbol NTLA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Intellia Therapeutics
Intellia Therapeutics offers a comprehensive portfolio of products and services, including Nexiguran Ziclumeran and CRISPR Programs. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
One-time treatment for ATTR Amyloidosis using genome editing.
Develops editing solutions for diseases like Hereditary Angioedema.
Unlock access to complete
Unlock access to complete
Leadership Team
62 people
Software Development Team
29 people
Senior Team
22 people
Operations Team
11 people
Product Management Team
10 people
Legal and Compliance
9 people
Finance and Accounting
9 people
Board Team
7 people
Unlock access to complete
Funding Insights of Intellia Therapeutics
Intellia Therapeutics has successfully raised a total of $85.02M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $70.02 million completed in September 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $70.0M
-
First Round
First Round
(18 Nov 2014)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2015 | Amount | Series B - Intellia Therapeutics | Valuation | Orbimed | |
| Nov, 2014 | Amount | Series A - Intellia Therapeutics | Valuation | Atlas Venture , Novartis |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Intellia Therapeutics
Intellia Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, Novartis and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Sectoral Asset Management is focused on global healthcare investment.
|
Founded Year | Domain | Location | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Intellia Therapeutics
Intellia Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Rewrite Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
DNA polymerization technology is developed for research applications.
|
2020 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Intellia Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Intellia Therapeutics Comparisons
Competitors of Intellia Therapeutics
Intellia Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Intellia Therapeutics
Frequently Asked Questions about Intellia Therapeutics
When was Intellia Therapeutics founded?
Intellia Therapeutics was founded in 2014.
Where is Intellia Therapeutics located?
Intellia Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Intellia Therapeutics a funded company?
Intellia Therapeutics is a funded company, having raised a total of $85.02M across 2 funding rounds to date. The company's 1st funding round was a Series A of $15M, raised on Nov 18, 2014.
How many employees does Intellia Therapeutics have?
As of Dec 31, 2024, the latest employee count at Intellia Therapeutics is 403.
What is the annual revenue of Intellia Therapeutics?
Annual revenue of Intellia Therapeutics is $57.88M as on Dec 31, 2024.
What does Intellia Therapeutics do?
Intellia Therapeutics was founded in 2014 in Cambridge, United States, within the biotechnology sector. Gene-editing technologies based on CRISPRCas9 are utilized to create therapeutics for blood disorders, cancer, and therapeutic protein production. Ex vivo applications are emphasized, where cells are genetically modified and reintroduced to patients. The lead candidate, NTLA-2002, targets hereditary angioedema through investigational CRISPR therapy. Operations focus on advancing these treatments for multiple diseases.
Who are the top competitors of Intellia Therapeutics?
Intellia Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does Intellia Therapeutics offer?
Intellia Therapeutics offers Nexiguran Ziclumeran and CRISPR Programs.
Is Intellia Therapeutics publicly traded?
Yes, Intellia Therapeutics is publicly traded on NASDAQ under the ticker symbol NTLA.
How many acquisitions has Intellia Therapeutics made?
Intellia Therapeutics has made 1 acquisition, including Rewrite Therapeutics.
Who are Intellia Therapeutics's investors?
Intellia Therapeutics has 8 investors. Key investors include Fidelity Investments, Novartis, Orbimed, Janus Henderson Investors, and Atlas Venture.
What is Intellia Therapeutics's ticker symbol?
The ticker symbol of Intellia Therapeutics is NTLA on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.